252 related articles for article (PubMed ID: 9233782)
21. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
22. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
[TBL] [Abstract][Full Text] [Related]
23. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of the FHIT gene in human prostate cancer.
Latil A; Bièche I; Fournier G; Cussenot O; Pesche S; Lidereau R
Oncogene; 1998 Apr; 16(14):1863-8. PubMed ID: 9583683
[TBL] [Abstract][Full Text] [Related]
25. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
26. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines.
Simon B; Bartsch D; Barth P; Prasnikar N; Münch K; Blum A; Arnold R; Göke B
Cancer Res; 1998 Apr; 58(8):1583-7. PubMed ID: 9563464
[TBL] [Abstract][Full Text] [Related]
27. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines.
Lee SH; Kim HY; Kim TJ; Park HK; Kim WH; Woo KM; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):39-49. PubMed ID: 15080495
[TBL] [Abstract][Full Text] [Related]
28. Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines.
Lee SH; Kim TJ; Kim HY; Kim JG; Park MK; Woo KM; Kim SH; Hwang KY; Nam HS; Min YK; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):145-57. PubMed ID: 15080505
[TBL] [Abstract][Full Text] [Related]
29. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
[TBL] [Abstract][Full Text] [Related]
30. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
31. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
32. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
[TBL] [Abstract][Full Text] [Related]
33. Role of TSG101 in uterine cervix cancer.
O'Boyle JD; Proctor ML; Fong KM; Lin WM; Miller DS; Muller CY
Gynecol Oncol; 1999 Dec; 75(3):401-5. PubMed ID: 10600297
[TBL] [Abstract][Full Text] [Related]
34. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.
Panagopoulos I; Pandis N; Thelin S; Petersson C; Mertens F; Borg A; Kristoffersson U; Mitelman F; Aman P
Cancer Res; 1996 Nov; 56(21):4871-5. PubMed ID: 8895736
[TBL] [Abstract][Full Text] [Related]
35. [Abnormal expression of the FHIT gene in human primary gastrointestinal cancers].
Duan XM; Zhang GY; Wu ES
Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):331-3. PubMed ID: 12205991
[TBL] [Abstract][Full Text] [Related]
36. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines.
Yanagisawa K; Kondo M; Osada H; Uchida K; Takagi K; Masuda A; Takahashi T; Takahashi T
Cancer Res; 1996 Dec; 56(24):5579-82. PubMed ID: 8971157
[TBL] [Abstract][Full Text] [Related]
37. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
[TBL] [Abstract][Full Text] [Related]
38. Aberrant FHIT transcripts in human colorectal cancers.
Lee SH; Lee SH
Res Commun Mol Pathol Pharmacol; 2005; 117-118():153-65. PubMed ID: 18426086
[TBL] [Abstract][Full Text] [Related]
39. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.
Sorio C; Baron A; Orlandini S; Zamboni G; Pederzoli P; Huebner K; Scarpa A
Cancer Res; 1999 Mar; 59(6):1308-14. PubMed ID: 10096564
[TBL] [Abstract][Full Text] [Related]
40. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
